Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...
Clinical Trials Arena on MSN3d
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-oldThe interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain muscle integrity compared with control.
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...
Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The ...
REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...
In a report released on March 14, Luca Issi from RBC Capital maintained a Buy rating on RegenXBio (RGNX – Research Report), with a price target ...
We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may ...
US biotech Regenxbio (Nasdaq: RGNX) has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) ...
Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback